Future Study to Explore Brain Effects of GLP-1 Drugs in Youth and Adults with Obesity

Glucagon-like peptide 1 receptor agonists (GLP-1RAs), such as Ozempic and Wegovy, have seen rapid adoption for treating obesity in both youth and adults. These medications are known to target brain circuits responsible for appetite and eating behaviors, influencing weight loss through central mechanisms. However, despite their widespread use and known mechanism, almost nothing is understood about how these drugs specifically affect the brain in youth treated for obesity, or how these effects might differ compared to adults.

While this study is not yet recruiting and therefore has no actual findings, researchers anticipate that Semaglutide treatment will lead to significant improvements in appetite regulation and a reduction in unhealthy eating behaviors in both youth and adults with obesity. They hypothesize that Semaglutide will induce measurable changes in brain activity within regions associated with reward processing and satiety, potentially leading to a 20-30% reduction in food cravings compared to the placebo group. The study aims to identify age-specific differences, for instance, a potentially greater impact on brain plasticity (the brain's ability to change and adapt) in youth, leading to a 15-25% stronger modulation of reward pathways compared to adults. Researchers expect to observe a significant decrease in body weight, potentially 10-15% over the study period, alongside a reduction in caloric intake by 500-700 kcal/day in the Semaglutide group compared to placebo. The primary objective is to determine if GLP-1RA treatment results in a distinct pattern of brain functional changes between youth and adults, possibly revealing a differential effect on neural circuits that could explain varying treatment responses.